Welcome to our dedicated page for Tenax Therapeutics news (Ticker: TENX), a resource for investors and traders seeking the latest updates and insights on Tenax Therapeutics stock.
Tenax Therapeutics Inc (TENX) is a clinical-stage pharmaceutical company developing therapies for cardiovascular and pulmonary diseases with high unmet needs. This page provides official updates on clinical trials, regulatory milestones, and corporate developments.
Investors and researchers will find a centralized repository of press releases and verified news related to Tenax's lead candidate levosimendan, including progress on the Phase 3 LEVEL study for PH-HFpEF. Track updates on intellectual property expansions, partnership announcements, and scientific presentations.
All content is curated to meet investor needs for timely, accurate information on drug development progress. Bookmark this page for direct access to primary source materials from Tenax Therapeutics, without promotional commentary or speculative analysis.
Tenax Therapeutics (TENX) announced significant updates regarding its lead product candidates, TNX-102 and TNX-201. The company received a Notice of Allowance from the USPTO for patent claims on subcutaneous levosimendan, expected to be issued in January 2022, extending coverage until 2039. Additionally, TNX-103 successfully transitioned patients from IV to oral levosimendan, demonstrating comparable efficacy and safety. Tenax plans to initiate a Phase 3 study for TNX-201 in pulmonary arterial hypertension in the second half of 2022, supported by a new Scientific Advisory Board of experts.
Tenax Therapeutics, a specialty pharmaceutical company, reported its third quarter 2021 financial results. The company is advancing its clinical programs, initiating a pharmacokinetic study for its novel imatinib formulation, with a Phase 3 trial expected to start in Q2 2022. Tenax has received FDA clearance for its IND application and published findings on levosimendan's novel mechanism. Third quarter R&D expenses rose to $1.2 million, while G&A expenses increased to $2.6 million. The net loss was $3.8 million, with $8.4 million in cash as of September 30, 2021, expected to sustain operations until Q2 2022.
Tenax Therapeutics (NASDAQ: TENX) has received FDA approval for its Investigational New Drug (IND) application for a reformulated delayed-release imatinib for pulmonary arterial hypertension (PAH). The company aims to initiate a Phase 3 trial in Q2 2022 following a comparative pharmacokinetic study starting in October 2021. This new formulation seeks to mitigate gastric intolerance seen in prior studies, enhancing patient tolerance and potentially offering a disease-modifying treatment option for this critical condition.
Tenax Therapeutics, Inc. (NASDAQ: TENX) has announced a presentation at the virtual Benzinga Healthcare Small Cap Conference on September 29, 2021, at 1:35 p.m. ET. The company's focus is on developing therapeutics for cardio-pulmonary diseases. Attendees can register for the webcast here. Tenax is advancing a delayed-release formulation of imatinib for pulmonary arterial hypertension (PAH), expecting to commence a pivotal trial in 1H 2022. They also hold rights to levosimendan, demonstrating promising Phase 2 results in heart failure.
Tenax Therapeutics, Inc. (NASDAQ: TENX) has announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The company specializes in therapeutics for cardio-pulmonary diseases. A pre-recorded presentation will be available for on-demand viewing starting September 13 at 7:00 A.M. (EST) on their website and through a provided webcast link. Tenax is advancing treatments like a delayed-release imatinib formulation and has acquired rights to develop levosimendan for pulmonary hypertension. More details can be found at tenaxthera.com.
Tenax Therapeutics (NASDAQ: TENX) reported its Q2 2021 financial results and highlighted progress in its clinical programs for pulmonary diseases. The company is advancing its imatinib program, which aims to improve treatment for pulmonary arterial hypertension, and the levosimendan study targeting pulmonary hypertension associated with left heart failure. Recent activities include a KOL webinar discussing levosimendan's potential and a publication regarding its mechanism of action. Financially, Tenax reported a net loss of $1.7 million, with $2.2 million in cash as of June 30, 2021. Following a recent equity offering, they anticipate sufficient funds through Q2 2022.
Tenax Therapeutics (Nasdaq: TENX) announced a significant publication about levosimendan, detailing its mechanism of action that improves cardiovascular hemodynamics in pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). The publication reveals that levosimendan reduces stressed blood volume, leading to lower pulmonary wedge pressure and central venous pressure without inotropic effects. This positions levosimendan as the first therapy to enhance exercise capacity in PH-HFpEF. A Phase III study is expected to start in the first half of 2022.
Tenax Therapeutics, Inc. (Nasdaq: TENX) announced a KOL webinar on Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) scheduled for August 16, 2021. KOL Daniel Burkhoff, M.D., Ph.D., will discuss treatment gaps and the potential of Levosimendan as a new therapy. Tenax's Chief Medical Officer, Stuart Rich, M.D., will outline the clinical development plan for Levosimendan, emphasizing its role as a first-in-class K-ATP activator. The event will include a Q&A session. Levosimendan has already shown potential benefits in clinical settings.
Tenax Therapeutics, Inc. (Nasdaq: TENX) announced a CEO transition with Anthony A. DiTonno retiring on July 13, 2021, after a decade of service. Christopher T. Giordano has been appointed as the new CEO, effective July 14, 2021. The company also secured a deal for selling 4,773,269 Units at $2.095 each, expecting gross proceeds of approximately $10 million. The Units consist of unregistered pre-funded and regular warrants to purchase common stock, with an aggregate of 9,546,538 underlying shares. This financing aims to enhance shareholder value through product development in cardiovascular and pulmonary diseases.
Tenax Therapeutics, Inc. (Nasdaq: TENX) will join the Russell Microcap® Index effective June 28, following the annual reconstitution. This inclusion increases visibility among institutional investors and aligns with the company’s growth strategy, as it advances its two lead drug programs, imatinib and levosimendan, towards Phase 3 trials. The Russell Microcap Index is widely recognized, with approximately $10.6 trillion in assets benchmarked to it, indicating significant attention for Tenax as it aims to address cardiovascular and pulmonary diseases.